INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases ...

Inovio Pharmaceuticals Inc (INO) addresses manufacturing issues and progresses towards BLA submission, despite financial hurdles and market uncertainties.

Inovio management emphasized steady progress toward BLA submission for INO-3107, with milestones on track for a potential FDA filing acceptance by year-end and a possible mid-2026 PDUFA date.